1. Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument. Issue 9 (September 2016) Authors: Walker, S. M.; Akdis, C.; Dahlen, S. E.; Djukanovic, R.; Edwards, J.; Garcia‐Marcos, L.; Johnston, S.; Kupczyk, M.; Martin, T.; Myles, D.; Palkonen, S.; Papadopoulos, N.; Powell, P.; Riley, J. Journal: Clinical & experimental allergy Issue: Volume 46:Issue 9(2016:Sep.) Page Start: 1136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TAK-659, a dual SYK/FLT3 inhibitor, leads to complete and sustained tumor regression and immune memory against tumor cells upon combination with anti-PD-1 agent. (December 2016) Authors: Kannan, K.; Riley, J.; Zhang, M.; Farrell, P.; Bailey, B.; Creson, J.; Fujitani, Y.; Yu, J.; Huck, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗